✨ Free AI Report
NRx Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research NRx Pharmaceuticals, Inc.
Company Research

NRx Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

NRx Pharmaceuticals, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Asymmetric risk/reward for speculators betting on regulatory approvals and clinic network scale, but significant execution risk and burn rate concerns limit institutional appeal. The company has significant clinical milestones and regulatory progress (NDA filing for NRX-100 in March 2025, anticipated NRX-101 NDA filing), plus strong partnerships including licensing discussions.

What is NRx Pharmaceuticals, Inc.'s industry? NRx Pharmaceuticals, Inc. (nrxpharma.com) operates in Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics. AskCyborg classifies NRx Pharmaceuticals, Inc. under Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics in its company registry.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders, particularly suicidal depression and PTSD. The company pursues a dual-path strategy...

5/ 10Mixed

Cyborg Score thesis

Asymmetric risk/reward for speculators betting on regulatory approvals and clinic network scale, but significant execution risk...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest NRx Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for NRx Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for NRx Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
NRx Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

NRx Pharmaceuticals, Inc. Overview

Pro stress-test →

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders, particularly suicidal depression and PTSD. The company pursues a dual-path strategy combining drug development of NMDA-targeted pharmaceuticals (NRX-100 and NRX-101) with a growing network of interventional psychiatry clinics through its HOPE Therapeutics subsidiary.

Strategic Profile

Pro stress-test →

NRx leverages a specialized NMDA platform targeting treatment-resistant psychiatric conditions with high unmet medical needs. The company combines biopharmaceutical development with clinic infrastructure, positioning itself uniquely at the intersection of drug development and mental health service delivery through its clinic network expansion strategy.

Competitive Landscape

Pro stress-test →

NRx operates in the treatment-resistant psychiatric therapeutics space competing indirectly with Janssen (esketamine/Spravato), established antidepressant manufacturers, and emerging neurotech companies. The NMDA platform focus and clinic network combination represent a differentiated but higher-risk approach compared to traditional pharma players. Direct competition comes from clinical-stage CNS companies pursuing similar neuropsychiatric indications.

Industry Context

NRx Pharmaceuticals, Inc. operates in Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics.

Key facts

Founded: 2015 · Headquarters: Wilmington, Delaware · Revenue: $0M · Market cap: $52.1M

What the analysts stress-tested

The top findings that survived the multi-agent debate for NRx Pharmaceuticals, Inc..

  • Advanced regulatory pipeline: NRX-100 NDA filed for suicidal depression treatment; NRX-101 pursuing Breakthrough Designation for bipolar depression with anticipated PDUFA dates before end of 2025
  • Clinic network expansion: Building HOPE Therapeutics clinic network for interventional psychiatry, attempting to create a differentiated integrated care model combining pharmacotherapy with clinical infrastructure
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025Initiated New Drug Application filing for NRX-100 (IV Ketamine) for suicidal depression treatment
  • March 2025Advanced NRX-101 toward NDA filing for Accelerated Approval under Breakthrough Designation for bipolar depression in akathisia-risk patients
  • +2 moreTrack every material event for NRx Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when NRx Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Spravato (esketamine)FDA-approved intranasal ketamine for treatment-resistant depression→Therapeutic platforms in PTSD/depressionClinical-stage therapies for severe psychiatric conditions→Ketamine-based interventionsEmerging clinic networks offering off-label ketamine treatments→

Compare NRx Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

NRx Pharmaceuticals, Inc. operates in Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Development / Clinical-Stage Psychiatric Therapeutics research →
NEW · MCP server

Ask your AI assistant about NRx Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare NRx Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did NRx Pharmaceuticals, Inc. do this quarter?”
“Is NRx Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does NRx Pharmaceuticals, Inc. do?+
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders, particularly suicidal depression and PTSD. The company pursues a dual-path strategy...
What is NRx Pharmaceuticals, Inc.'s Cyborg Score?+
NRx Pharmaceuticals, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are NRx Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Spravato (esketamine), Therapeutic platforms in PTSD/depression, Ketamine-based interventions. The full competitive landscape is in the AskCyborg report.
How can I get the full NRx Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the NRx Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track NRx Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical Development research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Protagonist Therapeutics Inc.6Biohaven Ltd.6Fortress Biotech, Inc.